Nature of Business
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. The company uses its broad and deep service offerings, its global footprint, and its therapeutic, scientific and analytics expertise to help biopharmaceutical customers, as well as other healthcare customers, navigate the increasingly complex healthcare environment to improve efficiency and deliver better healthcare outcomes.
Quintiles helps deliver new drugs and cures for the world’s most challenging diseases. Its 32,000 employees across the globe conduct business in approximately 100 countries and work each year with the top 20 biopharmaceutical companies. Quintiles has helped develop or commercialise each of the top 50 best-selling biopharmaceutical products and the top 20 best-selling biologic products on the market today.
We made a significant investment in the recapitalisation of Quintiles in January 2008, investing alongside Bain Capital, TPG and Quintiles CEO Dennis Gillings. Quintiles chose to partner with us due to our strong track record in the healthcare sector and our deep international network.
To assist in Quintiles’ continued growth, we have tapped into our extensive global healthcare network, which includes longstanding relationships with major pharmaceutical and biotech firms. As a result, we have introduced Quintiles to prospective healthcare customers across Europe and the US.
We introduced a member of our Business Leaders Network to serve as head of the EMEA Advisory Board, supported the company’s plans to expand further into Asia, assisted with the spin-off of the non-core NovaQuest entity and helped strengthen key positions within the management team.
In May 2013, Quintiles floated on the New York Stock Exchange. As part of this, 3i and funds managed by 3i, reduced their stake by approximately 10%, leaving us with a 12.3% stake.
Regulatory notice: This transaction involved a recommendation of 3i Corporation.